Acquired (Autoimmune) Hemolytic Anemia Market is expected to reach USD 992.28 million by 2029

PRESS RELEASE
Published October 4, 2023

Acquired (Autoimmune) Hemolytic Anemia Market  research report contains thorough information about target markets or customers. Analytical study of this market report aids in formulating growth strategies to augment sales and build brand image in the market. This market report supports the business to take better decisions for the successful future planning in terms of current and future trends in particular product or the industry. The key factors of Acquired (Autoimmune) Hemolytic Anemia Market  report consist of primary research, benchmarking studies, secondary research, company profiles, competitive intelligence & reporting, syndicated research, data collection, data processing and analysis, survey design, and survey programming.

Hemolytic anemia is a type of anemia that occurs when your red blood cells break down or die quicker than your body can replace them with new ones. Hemolytic anemia can be caused by inheriting anemia-causing genetic disorders, infections, or specific drugs. Hemolytic anemia treatment varies based on the origin of the sickness. Blood transfusions, corticosteroid medications, and Rituximab are all possible treatments. Surgery to remove the spleen is recommended in more severe cases. Warm antibody hemolytic anemia and cold antibody hemolytic anemia are two types of acquired (autoimmune) hemolytic anemia. Autoantibodies attach to red blood cells in warm antibody hemolytic anemia and destroy them at a temperature higher than body temperature; in cold antibody hemolytic anemia, self-generated antibodies kill red blood cells at a temperature lower than body temperature.

Data Bridge Market Research analyses that the acquired (autoimmune) hemolytic anemia market was valued at USD 676.75 million in 2021 and is expected to reach USD 992.28 million by 2029, registering a CAGR of 4.90% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Request a Sample PDF:  https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-acquired-autoimmune-hemolytic-anemia-market&Shri

Non-genetic acquired (autoimmune) hemolytic anemia arises when the body’s own immune system eliminates healthy tissues in response to invading organisms such as lymphocytes and antibodies. The treatment focuses on three main goals: preventing RBC destruction, raising RBC count, and treating the underlying ailment. Major treatment options include blood transfusions, medicines, plasmapheresis, and procedures. To treat acquired (autoimmune) hemolytic anemia, medicines such as prednisone, rituximab, hydroxyurea, and cyclosporine are commonly used.

Opportunities

  • Rise in R&D activities  

The market’s growth is fueled by growing number of research and development activities. This will provide beneficial opportunities for the acquired (autoimmune) hemolytic anemia market growth.

Moreover, the market’s growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the acquired (autoimmune) hemolytic anemia market growth.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the growth rate of the acquired (autoimmune) hemolytic anemia market during 2022-2029. The lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the acquired (autoimmune) hemolytic anemia market. Additionally, lack of awareness among people and poor reimbursement policies will restrain and further impede the market’s growth rate during the forecast period of 2022-2029.

This acquired (autoimmune) hemolytic anemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acquired (autoimmune) hemolytic anemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In February 2022, The U.S. Food and Drug Administration (FDA) announced the approval of Enjaymo (sutimlimab-jome). It decreases red blood cell transfusion requirement due to hemolysis in adults with cold agglutinin disease (CAD). Enjaymo is the first as well as only approved treatment for people with CAD and functions by inhibiting the destruction of red blood cells (hemolysis).

Browse Complete Report Details-  https://www.databridgemarketresearch.com/reports/global-acquired-autoimmune-hemolytic-anemia-market?Shri

Acquired (Autoimmune) Hemolytic Anemia Market Scope

The acquired (autoimmune) hemolytic anemia market is segmented on the basis of types, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

  • Warm Autoimmune Induced Hemolytic Anemia
  • Cold Agglutinin Disease (CAD)
  • Others

Treatment

  • Medication
  • Corticosteroids
  • Immunosuppressive agents
  • Others
  • Blood Transfusion
  • Surgery
  • Splenectomy
  • Others

Diagnosis

  • Blood Tests
  • Coombs Test
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the this market
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the market
  • Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the market
  • Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

Critical Insights Related to This Market Included in the Report:

  • Exclusive graphics and Illustrative SWOT analysis of some of the leading companies in this market
  • Value chain analysis of prominent players in the market
  • Current trends influencing the dynamics of this market across various geographies
  • Recent mergers, acquisitions, collaborations, and partnerships
  • Revenue growth of this industry over the forecast period
  • Marketing strategy study and growth trends
  • Growth driven factor analysis
  • Emerging recess segments and region-wise market
  • An empirical evaluation of the curve of this market
  • Ancient, Present, and Probable scope of the market from both prospect value and volume

Browse Detailed Summary of Research Report with TOC:  https://www.databridgemarketresearch.com/toc/?dbmr=global-acquired-autoimmune-hemolytic-anemia-market&Shri

Some of the major players operating in the acquired (autoimmune) hemolytic anemia market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd.(Ireland)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • AbbVie Inc. (U.S.)
  • Fresenius SE & Co. KGaA (Germany)
  • Lupin (India)
  • ViforPharma Ltd. (Switzerland)
  • AMAG Pharmaceuticals (U.S.)
  • Akebia Therapeutics, INC. (U.S.)
  • CHO-A Pharmaceutical CO., LTD. (South Korea)
  • Orion Corporation (Finland)
  • Pharmacosmos A/S (Denmark)
  • Shield Therapeutics (U.K.)
  • Advanz Pharmaceutical (U.K.)
  • Alkem Labs (India)
  • Zydus Cadila (India)
  • Hikma Pharmaceuticals PLC (U.K.)

Top DBMR Healthcare Reports:        

Global Bipolar Disorder Treatment Market – Industry Trends and Forecast to 2029

Global Diabetic Macular Edema Treatment Market – Industry Trends and Forecast to 2029

Global 3D Cone Beam Computed Tomography (CBCT) Systems Market – Industry Trends and Forecast to 2029

Global Pregnancy Care Products Market – Industry Trends and Forecast to 2029

Global Hair and Care Market – Industry Trends and Forecast to 2030

Global Vascular Stent Market – Industry Trends and Forecast to 2029

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com

CDN Newswire